For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter ...

Limited (“HUTCHMED”, the “Company” or “we”) (HKEX:13; Nasdaq/AIM:HCM) today reports its financial results for the year ended December 31, 2024 and provides updates on key clinical and commercial ...